Neurogene (NGNE) 10-K2022 FY Annual report

Filed: 20 Mar 23, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: acute, andDecember, andhad, ASH, attrition, begun, beneficiary, bid, buy, ceiling, computationally, conflict, consecutive, conservation, conserve, consummate, consummated, consummation, convened, corroborated, counterparty, culminated, dangling, delisted, delisting, deveopment, dissolution, dissolve, divestiture, DNA, donut, downturn, economy, encoded, ensuing, environment, era, Excellence, exhausting, fewer, formula, foster, frame, FrontRunner, gathered, geopolitical, grace, hamper, headcount, hierarchy, hole, hybrid, inflationary, invasion, IRA, levied, lifted, light, line, machine, macroeconomic, minimal, morale, neural, optimum, orderly, ourcertificate, ourdevelopment, paradigm, passage, penalize, prespecified, quoted, ratio, recession, regain, reorganization, resume, resumed, resumption, retaliation, reverse, runway, Russia, scarcity, Secretary, shareholder, Society, spec, spent, split, sublease, sublessee, subsidize, te, technique, thousand, transportation, turnover, Ukraine, unadjusted, undertaken, unemployment, unintended, unobservable, unrealized, weak, wider, wind, winding, wrongdoing

Removed: actively, aldesleukin, algorithm, AMP, apportioned, autoimmune, bacteria, biased, bind, Chief, circumvent, clarifying, commonly, comparative, Concurrently, conformational, consolidation, contact, cultivated, degradation, dispensed, effector, eliminating, endothelial, exacerbate, experimental, extending, fastest, feedback, Finally, frequently, function, gap, globe, grow, growing, homology, hypotension, idealized, innovator, Institute, intercompany, interface, investigative, kidney, killer, kinase, leak, leasehold, leverage, liver, loosen, mandated, mental, mitigated, modest, modifying, mount, murine, NK, notable, optimizing, oral, originally, outpatient, oversee, posed, Poverty, powered, preferentially, proliferation, proteolytic, proven, qualifying, recombinant, removing, repealing, retroactive, rosiptor, selective, selectivity, shared, signaling, Simplifying, social, stay, storm, syngeneic, treated, Trump, tyrosine, Vancouver, vascular, VEGF, wholly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

NGNE similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

NEOLEUKIN THERAPEUTICS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Neoleukin Therapeutics, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Jonathan G. Drachman, President and Chief Executive Officer of the Company certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

IN WITNESS WHEREOF, the undersigned has set their hand hereto as of March 20, 2023.



/s/ Jonathan G. Drachman
Jonathan G. Drachman
President and Chief Executive Officer
(Principal Executive and Financial Officer)

This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Neoleukin Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.